Informed Consent: the Rate-Limiting Step in Acute Stroke Trials

Successful implementation of a randomized clinical trial (RCT) for neuro-vascular emergencies such as cerebral infarction, intracerebral hemorrhage (ICH), or subarachnoid hemorrhage (SAH) is difficult. Besides establishing an accurate, hyper-expedited diagnosis among many mimics in a person with ac...

Full description

Bibliographic Details
Main Authors: David Z Rose, Scott E Kasner
Format: Article
Language:English
Published: Frontiers Media S.A. 2011-10-01
Series:Frontiers in Neurology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fneur.2011.00065/full
id doaj-43502f5f69824372ad2b64521cb5bca2
record_format Article
spelling doaj-43502f5f69824372ad2b64521cb5bca22020-11-24T22:22:15ZengFrontiers Media S.A.Frontiers in Neurology1664-22952011-10-01210.3389/fneur.2011.0006514332Informed Consent: the Rate-Limiting Step in Acute Stroke TrialsDavid Z Rose0Scott E Kasner1University of South FloridaUniversity of PennsylvaniaSuccessful implementation of a randomized clinical trial (RCT) for neuro-vascular emergencies such as cerebral infarction, intracerebral hemorrhage (ICH), or subarachnoid hemorrhage (SAH) is difficult. Besides establishing an accurate, hyper-expedited diagnosis among many mimics in a person with acute neurological deficits, informed consent must be obtained from this vulnerable group of patients who may be unable to convey their own wishes, grasp the gravity of their situation, or give a complete history or examination. We review the influences, barriers, and factors investigators encounter when providing established and putative stroke therapies, and focus on informed consent, the most important research protector of human subjects, as the rate-limiting step for enrollment into acute stroke RCTs. The informed consent process has received relatively little attention in the stroke literature, but is especially important for stroke victims with acute cognitive, aural, lingual, motor, or visual impairments. Consent by a surrogate may not accurately reflect the patient’s wishes. Further, confusion about trial methodology, negative opinions of placebo-controlled studies, and therapeutic misconception by patients or surrogates may impede trial enrollment and requires further study. Exception From Informed Consent (EFIC) offers an opportunity that is rarely if ever utilized for stroke RCTs. Ultimately, advancing the knowledge base and treatment paradigms for acute stroke is essential but autonomy, beneficence (non-malfeasance), and justice must also be carefully interwoven into any well-designed RCT.http://journal.frontiersin.org/Journal/10.3389/fneur.2011.00065/fullCerebral InfarctionInformed ConsentSubarachnoid Hemorrhageintracerebral hemorrhageclinical trialsplacebo
collection DOAJ
language English
format Article
sources DOAJ
author David Z Rose
Scott E Kasner
spellingShingle David Z Rose
Scott E Kasner
Informed Consent: the Rate-Limiting Step in Acute Stroke Trials
Frontiers in Neurology
Cerebral Infarction
Informed Consent
Subarachnoid Hemorrhage
intracerebral hemorrhage
clinical trials
placebo
author_facet David Z Rose
Scott E Kasner
author_sort David Z Rose
title Informed Consent: the Rate-Limiting Step in Acute Stroke Trials
title_short Informed Consent: the Rate-Limiting Step in Acute Stroke Trials
title_full Informed Consent: the Rate-Limiting Step in Acute Stroke Trials
title_fullStr Informed Consent: the Rate-Limiting Step in Acute Stroke Trials
title_full_unstemmed Informed Consent: the Rate-Limiting Step in Acute Stroke Trials
title_sort informed consent: the rate-limiting step in acute stroke trials
publisher Frontiers Media S.A.
series Frontiers in Neurology
issn 1664-2295
publishDate 2011-10-01
description Successful implementation of a randomized clinical trial (RCT) for neuro-vascular emergencies such as cerebral infarction, intracerebral hemorrhage (ICH), or subarachnoid hemorrhage (SAH) is difficult. Besides establishing an accurate, hyper-expedited diagnosis among many mimics in a person with acute neurological deficits, informed consent must be obtained from this vulnerable group of patients who may be unable to convey their own wishes, grasp the gravity of their situation, or give a complete history or examination. We review the influences, barriers, and factors investigators encounter when providing established and putative stroke therapies, and focus on informed consent, the most important research protector of human subjects, as the rate-limiting step for enrollment into acute stroke RCTs. The informed consent process has received relatively little attention in the stroke literature, but is especially important for stroke victims with acute cognitive, aural, lingual, motor, or visual impairments. Consent by a surrogate may not accurately reflect the patient’s wishes. Further, confusion about trial methodology, negative opinions of placebo-controlled studies, and therapeutic misconception by patients or surrogates may impede trial enrollment and requires further study. Exception From Informed Consent (EFIC) offers an opportunity that is rarely if ever utilized for stroke RCTs. Ultimately, advancing the knowledge base and treatment paradigms for acute stroke is essential but autonomy, beneficence (non-malfeasance), and justice must also be carefully interwoven into any well-designed RCT.
topic Cerebral Infarction
Informed Consent
Subarachnoid Hemorrhage
intracerebral hemorrhage
clinical trials
placebo
url http://journal.frontiersin.org/Journal/10.3389/fneur.2011.00065/full
work_keys_str_mv AT davidzrose informedconsenttheratelimitingstepinacutestroketrials
AT scottekasner informedconsenttheratelimitingstepinacutestroketrials
_version_ 1725769152801538048